 MENLO PARK, Calif., Nov. 18, 2020 GLOBE NEWSWIRE -- Corcept Therapeutics Incorporated NASDAQ: CORT, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that the Patent Trial and Appeal Board PTAB of the U.S. Patent and Trademark Office has issued a decision upholding the validity of all claims of U.S. Patent No. 10,195,214, Concomitant Administration of Glucocorticoid Receptor Modulators and CYP3A Inhibitors the 214 patent. The 214 patent expires in 2037. 